January 15, 2008 - Kamada (TASE: KMDA), a biopharmaceutical company developing, producing and marketing specialty life-saving therapeutics, has successfully concluded Phase I clinical studies designed to test the safety and tolerability of the aerosolized version of its flagship product, Alpha-1 Antitrypsin (AAT) using an optimized 
eFlow Electronic Nebulizer (PARI Pharma GmbH) to treat various lung diseases... Kamada's Press Release - PARI 's Press Release-
